JP2006241119A - Food composition containing carbohydrate decomposition enzyme inhibitory substance derived from rosa rugosa flower and method for producing the food composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a food composition as food material considered as affording the correction of hyperglycemia after meal through paying attention to highly safe food to prevent diabetes in view of the fact that as for diabetes involving complication progression and difficult to entirely cure, prevention should be considered as top priority rather than treatment. <P>SOLUTION: The food composition contains an inhibitory substance for α-glucosidase and α-amylase obtained by extraction of Rosa rugosa flowers with water or an aqueous solution. This food composition is effective for preventing diabetes. The above inhibitory substance is produced by extraction of Rosa rugosa flowers with water or an aqueous solution. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to a food composition containing a carbohydrase inhibitor extracted from a flower of Hermanus (Rosa rugosa) and a method for producing the same.

  In recent years, diabetes has increased explosively around the world. In diabetes, blood vessels are gradually damaged by hyperglycemia and abnormalities occur in various organs. Diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy have been known as three major complications for some time, but in recent years it is also known that the risk of developing arteriosclerosis is increased. In addition, there is diabetic coma (ketoacidosis, hyperosmotic coma, lactic acidosis) due to hyperglycemia itself, which may lead to death.

  There are two groups of diabetes, classified as type I diabetes and type II diabetes.

  Type I diabetes is defined as “diabetes caused by insulin deficiency due to destruction of pancreatic β cells” (see Non-Patent Documents 1, 2, 3, etc.). There are two possible causes of this, namely "autoimmunity" due to helper T cell abnormalities and "idiopathic" of unknown cause, and it is characterized by many occurrences in early childhood.

  On the other hand, type II diabetes does not have an absolute deficiency of insulin, as was said to be non-insulin-dependent diabetes, but it is a target of liver, muscle, adipose tissue, etc. It is thought to develop as a result of the concomitant “decreased insulin sensitivity” in the organ.

  Diabetes mellitus, which has been increasing rapidly recently, is derived from type II, and is considered to account for 90 to 95% of diabetes. Type II diabetes is caused by modern social life such as stress, obesity, intake of high-calorie foods due to a decline in basic metabolic capacity due to lack of exercise, and so on. Complications due to diabetes are caused by chronic hyperglycemia, and it is considered essential for treatment and prevention to correct dietary deficits and lack of exercise, given that it has a devastating effect on life later.

  Blood glucose is controlled by insulin and is kept at a constant level by fasting basal secretion and immediate additional secretion corresponding to postprandial blood glucose rise. In type II diabetes, basal secretion is rarely impaired. However, since the additional secretion is not sufficiently performed, the blood sugar level of the next meal rises until the blood sugar level becomes normal, and always becomes high. It also helps to reduce sensitivity, leading to chronic hyperglycemia. Hyperglycemia together with hyperlipidemia has a toxic effect on pancreatic β cells and insulin target organs, and further leads to a vicious cycle that leads to hyperglycemia.

  Treatment of type II diabetes, which is primarily aimed at preventing complications, sometimes requires insulin therapy (fast-acting, super-fast-acting), but most is due to oral medication, improving insulin secretion, improving resistance and It is postprandial hyperglycemia improvement.

  A sulfonylurea drug binds to a sulfonylurea receptor (SUR receptor) protein present in pancreatic β-cells, and as a result of depolarization, voltage-dependent calcium channels are opened to promote insulin secretion. Tolbutamide was clinically introduced in 1956 and has the oldest history of oral medications. Recently, glibenclamide, which has a strong secretion promoting action, has also been developed. As a side effect, hypoglycemia occurs when insulin secretion becomes excessive. Many other side effects have been reported, including increased enzyme efflux from the liver, hematopoietic disorders such as granulocytopenia and thrombocytopenia, and digestive symptoms. In addition, glibenclamide is prohibited in principle when there are renal complications.

  Sulfonylurea drugs have a slow onset of action and are insufficient to correct postprandial hyperglycemia. Thus, meglitinide-based drugs such as nateglinide, repaglinide, and mitiglinide have been developed by modifying the sulfonylurea glibenclamide. Nateglinide currently used in Japan, like sulfonylurea drugs, binds to receptors and then increases intracellular calcium ion concentration and promotes insulin secretion by cell membrane depolarization. This drug is characterized by weak binding to SUR, fast dissociation, fast absorption from the gastrointestinal tract, and rapid inactivation in the liver. In this way, it is effective for postprandial hyperglycemia because of its fast action time and short duration. In clinical trials for type II diabetic patients using nateglinide, not only postprandial blood glucose level, but also postprandial blood insulin level, glycated hemoglobin level There is a report that exerted an effect on fasting blood glucose level (see, for example, Non-Patent Document 4). Postprandial hyperglycemia has been suggested as a risk factor for cardiovascular disease (see, for example, Non-Patent Documents 5 and 6). Postprandial hyperglycemia is important not only for fasting blood glucose but also for suppression of complications. Has been. In that sense, there is high expectation for the effects of haste insulin secretagogues. However, as side effects, there are limitations such as hypoglycemia and acute liver damage, and inability to apply to patients with renal failure.

  The above drugs induce insulin secretion and do not compensate for decreased insulin sensitivity. Known as sensitivity-reducing agents are biguanide and thiazolidine derivatives.

Biguanides have no known mechanism of action, but increased insulin sensitivity has been observed. Moreover, the hypoglycemic effect is mainly brought about by suppression of glucose release from the liver and suppression of hepatic gluconeogenesis. Biguanides were marketed in late 1950 in the form of phenformin, buformin, and metformin. However, phenformin was discontinued in the 1970s due to its involvement in the development of lactic acidosis. Therefore, it is strictly prohibited if there is a risk of developing lactic acidosis, such as a patient with renal impairment, hypoxemia, or metabolic acidosis. Other side effects include gastrointestinal disorders such as abdominal pain, diarrhea, and vomiting, liver dysfunction, and vitamin B ₁₂ absorption inhibition.

  Similarly, the mechanism for improving resistance of thiazolidine derivatives is not known, but thiazolidine derivative drugs act on muscle and adipose tissue, and exhibit glucose lowering action by promoting glucose uptake. Side effects include liver damage and worsening of heart failure, as well as fulminant hepatitis seen in the first troglitazone, although there are no reports of thiazolidine derivatives currently on the market.

  All the drugs mentioned so far act on the insulin secretion deficiency and resistance improvement seen in type II diabetes. In mildly diabetic patients, insulin secretion is slow, but often shows delayed hypersecretion after meals. Therefore, blood sugar control becomes possible by adjusting the secretion phase of insulin to postprandial hyperglycemia. This can be achieved by delaying postprandial hyperglycemia as much as possible. Postprandial hyperglycemia is caused by carbohydrases (mainly α-amylase and α-glucosidase) breaking down carbohydrates into glucose, so competitive inhibitors can delay the increase in blood glucose. Currently, Acarbose and Voglibose are used as α-glucosidase inhibitors, and there are reported examples in which the onset of type II diabetes is significantly suppressed (see, for example, Non-Patent Documents 7 and 8). In addition, the merit of this drug is that it does not affect the blood insulin concentration and therefore has a much lower risk of hypoglycemia than other hypoglycemic drugs. However, characteristic side effects of this drug include increased paralysis, abdominal fullness, and diarrhea. Intestinal obstruction and liver dysfunction have also been reported, and caution is required in use.

  As described above, the action and side effects of oral hypoglycemic drugs used for the treatment of diabetes have been described. In addition to these, insulin secretion promoters are known to have increased obesity. Since obesity worsens insulin resistance, type II diabetes may develop. Furthermore, since obesity is a risk factor for arteriosclerosis such as myocardial infarction, it may lead to a situation in which the risk of vascular injury is increased despite the treatment of diabetes.

  In summary, oral hypoglycemic drugs have various side effects such as hypoglycemia that sometimes falls into a coma, liver / kidney disorders, and digestive symptoms. Most drugs are prohibited from use when organ damage is observed. Diabetes is difficult to cure once it develops, requiring symptomatic treatment including insulin therapy. This means that medication is always required during meals. Correspondingly, the burden on the patient is heavy also in the economic aspect. Furthermore, as the aging society continues to advance, the medical cost problem is expected to become serious, so it is important how to prevent diabetes.

  Type II diabetes is caused by genetic and environmental factors (exercise, diet, stress, etc.). However, environmental factors are particularly strong, and it is said that oral hypoglycemic drugs are only meaningful when there is proper exercise and diet in treatment. However, due to time constraints, there is almost no subjective symptom in diabetes itself, so it is difficult for modern people to pay attention to exercise and diet before becoming diabetic. Also, drug prevention is not possible because it cannot be purchased without a doctor's prescription.

  As mentioned above, the progression of complications and diabetes that is difficult to cure once onset should be prevented first, not treated. Although it has been reported that type II diabetes is suppressed by drugs (see, for example, Non-Patent Documents 9, 10, and 11), it is inappropriate and practically impossible to use drugs for prevention due to numerous side effects. It is. So we focused on food. Food is an essential part of life and therefore has many opportunities for consumption. Furthermore, since it is a food, safety is high. In other words, food is considered an excellent material for prevention.

  As seen in drugs, postprandial hyperglycemia can be promoted by insulin secretion, insulin resistance, and delayed digestion / absorption due to inhibition of glycolytic enzymes. Seem. The reason for this is that it can be said that saccharide-degrading enzyme inhibitors have fewer side effects overall. The risk of hypoglycemia that is of most concern with oral diabetes drugs is particularly low with this drug. In addition, as other side effects, increased puerperium and diarrhea are observed at the initial stage of administration, but they disappear rather than chronically. And insulin secretagogues and resistance-improving drugs are symptomatic treatments and have no effect on improving the constitution. However, if improvement in postprandial hyperglycemia is observed by inhibition of saccharide-degrading enzymes, there is a high possibility that it will lead to the ability of humans to secrete insulin and perception.

The expert committee on the diagnosis and classification of diabetes mellitus (1997): Diabetes Care 20, p.1183 Alberti KG, Zimmet PZ for the WHO consultation (1998): Diabet Med 15, p.539 Ken Katsuraya et al .: Committee report on classification and diagnostic criteria of diabetes (1999), Diabetes 42, p.385 Kosaka, J. et al .: 1997, Pharmacology and Clinical 7, p.669 DECODE Study Group: 2001, Arch Intern Med 161, p.397-405 Tominaga M et al.:1999,Diabetes Care 22, p.920-924 Chiasson JL et al .: 1998, Diabetes Care 21, p. 1720-1725 Chiasson JL et al .: 2002, Lancet 359, p. 2072-2077 Johansen K: 1999, Diabetes Care 22, p.33-37 Chiasson JL et al .: 1998, Diabetes Care 21, p. 1720-1725 Chiasson JL et al .: 2002, Lancet 359, p. 2072-2077

  Diabetes, whose complications are difficult to develop or difficult to cure, should be given priority to prevention rather than treatment, but the use of drugs in prevention has been inappropriate and virtually impossible due to numerous side effects. So we focused on food. Foods are indispensable for daily life, and therefore, there are many opportunities to take them, and since they are foods, they are highly safe. In other words, food is considered an excellent material for prevention. Repeating a postprandial hyperglycemia state leads to abnormal glucose tolerance, which eventually leads to type II diabetes. Therefore, since correcting postprandial hyperglycemia has great significance for the prevention of diabetes, the provision of such food materials was the subject of diabetes prevention.

  As a result of extensive studies, we divided the edible material into a water-soluble fraction and an organic solvent fraction, and searched for α-glucosidase inhibitory components using an in vitro system. As a result, the present inventors have found that the water-soluble fraction of the flowers of Hermanus (Rosaceae, scientific name: Rosa rugosa) that has been drunk as Mayui tea has high inhibitory activity, and thus completed the present invention.

  That is, a food composition comprising one or two inhibitors of α-glucosidase and α-amylase obtained by extraction from a flower of Hermanus with water or an aqueous solution. It is preferable that the flower of the genus is a makey tea.

  The second aspect of the present invention is a method for producing one or two inhibitors of α-glucosidase and α-amylase, which are extracted from flowers of Hermanus with water or an aqueous solution.

  The third aspect of the present invention is the inhibition of any one or two of α-glucosidase and α-amylase, wherein the flower is extracted from a flower of Hermanus with water or an aqueous solution at 60 to 100 ° C. for 5 to 15 minutes. It is a manufacturing method of a substance.

  A fourth aspect of the present invention is the production of a beverage characterized in that it contains any one or two inhibitors of α-glucosidase and α-amylase obtained by extraction from flowers of Hermanus with water or an aqueous solution. Is the method.

  According to a fifth aspect of the present invention, any one or two inhibitors of α-glucosidase and α-amylase obtained by extraction from a flower of Hermanus with water or an aqueous solution are added to the food material. It is a manufacturing method of a food composition.

  As described above, diabetes should be considered as the first prevention, and food, not drugs, is considered a good material. The saccharide-degrading enzyme inhibitor derived from the flowers of the present invention is highly safe and effective in improving postprandial hyperglycemia. If postprandial hyperglycemia is improved on a daily basis, insulin secretion ability and insulin resistance will be improved as secondary effects.

  Examples of reports on the genus Hermanus that have led to the present invention include anti-inflammatory action (see, for example, Non-patent Document 12), antioxidative lipid oxidation-inhibiting action (for example, see Non-Patent Document 13), and anti-cancer action (for example, non-patent document 12). Patent Document 14) and differentiation-inducing ability (for example, see Non-Patent Document 15) and the like, but there has been no report to date that there is a carbohydrase inhibitory effect. Recently, Pterocarpus (Pterocarpus marsupium), Mulberry (Morus alba), Kumisctin (Orthosiphon aristatus), Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosan keri (Low) There is an invention (for example, see Patent Document 1) that an extract of asphodeloides) is effective in the treatment and prevention of diabetes. In this invention, the saccharide-degrading enzyme inhibitory effect is described, but this is a mixture of extracts and not an extract from a flower of Hermanus.

  At present, guava tea and indigestible dextrin are distributed as foods with a blood glucose lowering effect. However, the extract of water or an aqueous solution from the flowers of the present invention of the present invention was stronger in the maltase activity inhibition effect and the sucrase activity inhibition effect than guava tea. Therefore, it is suggested that the extract of water or aqueous solution from the flowers of the present invention is more effective in improving postprandial hyperglycemia than guava tea having the same mechanism of action.

On the other hand, details of the effect of suppressing the increase in blood glucose level by indigestible dextrin are still unknown. However, there is a report (for example, see Non-Patent Document 16) that an indigestible dextrin suppresses an increase in blood glucose after administration of sucrose, maltose, and maltodextrin, and it acts on a disaccharide-degrading enzyme-specific transporter. It is considered (for example, refer nonpatent literature 17).
Therefore, the action mechanism is different from the inhibitors of α-glucosidase and α-amylase of the present invention, and the effectiveness of the blood glucose lowering effect cannot be discussed. However, indigestible dextrin has a low yield in a general method (for example, Non-Patent Document 18), and it is necessary to strictly control production conditions such as temperature and reaction time. Indigestible dextrin is generally obtained by subjecting starch to a high temperature (100 ° C. to 220 ° C.) for a long time (3 hours to 20 hours). However, the yield of indigestible dextrin obtained by this method is only 30%, and when heating conditions are changed to improve the yield, it increases to about 60%, but since colored substances and irritating odors are also generated, A purification process is required. As an improvement method thereof, there is a production method in which the yield of an indigestible portion is improved by heat-treating starch with hydrochloric acid and then performing enzyme treatment with α-amylase and glucoamylase (for example, Patent Documents 2 and 3) reference). However, this production method requires a neutralizing action because the enzyme does not work under acid conditions. After the enzyme reaction, decolorization with activated carbon, filtration, desalting and decolorization with an ion exchange resin are performed, and purification by ion exchange chromatography is performed to remove digestible glucose and the like. As described above, the production of indigestible dextrin requires many steps, and considering temperature control management, it can be said that stable supply and quality maintenance at an industrial level are very difficult.

  On the other hand, according to the present invention, one or two inhibitors of α-glucosidase and α-amylase obtained by extraction from a flower of Hermanus with water or an aqueous solution are extracted with water or an aqueous solution. It is a manufacturing method of a step process. Even if this is developed to the industrial level, it is possible to meet the socially required stable supply and quality assurance.

JP 2005-500263 Publication Japanese Patent Laid-Open No. 5-178902 Japanese Patent Laid-Open No. 5-148301 Hyu-Ju Jung et al .: 2005, Biol. Pharm. Bull 28 (1), p. 101-104 Cho EJ et al: 2003, Am J Chin Med 31 (6), p.907-917 Yoshizawa Y et al.:2000, Anticancer Res. Nov-Dec 20 (6B), p.4285-4289 Yoshizawa Y et al.:2000, J Agric Food Chem Aug 48 (8), p.3177-3182 Wakabayashi et al .: 1995, J Endocrinol. Mar 144 (3), p.533-538 Wakabayashi S.:1992, Nippon Naibunpi Gakkai Zasshi Jun 20 (68), p.623-635 Tomasik, K. & Wiejak, P .: 1990, Advance in Carbohydrate Chemistry (47), p.279-343

  The Hermanus referred to in the present invention is a Rosaceae plant, and its scientific name is called Rosa rugosa. In addition, a flower is a bud with a collection of sepals, a flower crown with a collection of petals, a flower bud with a stamen and a pistil in an angiosperm, but the flower according to the present invention contains a floral pattern in the above. It does not matter whether it is in a dry state or an undried state. Therefore, what is called “Maigui” in China is included in the flower of the present invention because it is a dried flower of the flower.

  The water or aqueous solution of the present invention refers to tap water, distilled water, ion-exchanged water or an aqueous buffer solution, and these are added to the flowers of the genus flowers, left standing or stirred, and the obtained extract is separated from the flowers of the genus flowers. In order to achieve this, one or two inhibitors of α-glucosidase and α-amylase can be obtained by filtering with gauze or the like. As extraction conditions, the temperature of water or an aqueous solution is preferably 60 ° C. to 100 ° C., and the extraction time is preferably 5 minutes to 15 minutes because of high extraction efficiency. In addition, it is particularly preferable to crush the flowers of the genus flowers with a mixer or the like because the extraction efficiency of the inhibitor increases.

  The degree of the inhibitory effect on the α-glucosidase activity referred to in the present invention can be obtained by measuring the maltose and sucrase decomposing activities by α-glucosidase (maltase and sucrase) under the conditions where the extract is added and not added. A general method is to evaluate the inhibitory effect by quantifying the amount of glucose produced by the glucose oxidase method. However, in the glucose oxidase method, glucose is oxidized to generate gluconic acid and hydrogen peroxide, and the hydrogen peroxide generates color by reducing the chromogenic substrate. . Therefore, in this invention, the inhibitory effect was evaluated by detecting produced | generated glucose with a differential refractometer.

  The degree of the inhibitory effect of α-amylase activity referred to in the present invention can be obtained by measuring the amylolytic activity by α-amylase under the conditions of adding and not adding the extract. The activity is measured by coloring the iodine starch reaction, and the amount of starch remaining in the reaction solution is measured by absorbance. However, some samples need to be diluted to significantly inhibit the color development of the iodine starch reaction.

  The food material referred to in the present invention refers to a raw material of food, and the food composition refers to a material that is made of various food materials and can be eaten as it is or processed. Therefore, beverages are also included in the food composition referred to in the present invention.

  EXAMPLES The present invention will be specifically described below with reference to examples, but the gist of the present invention is not limited by these examples.

Example 1
The extract of the genus flower used in this example (hereinafter referred to as “the genus extract”) and the extract of guava leaf (hereinafter referred to as the “guava extract”) are 200 ml of distilled water with respect to 10 g of the dry ground sample. The extraction was performed. The extraction conditions were 100 ° C. and 10 minutes. The extract was separated by gauze, and each extract was made into each extract using supernatant obtained by centrifugation at 15,000 × g for 5 minutes.

(Test Example 1)
The preparation of α-glucosidase and the definition of enzyme unit are as follows. Rat small intestine acetone powder (manufactured by Sigma) was suspended in 250 mM maleate buffer (pH 6.0), and centrifuged at 5000 × g for 10 minutes to obtain a supernatant. Further, the supernatant was centrifuged at 15,000 × g for 15 minutes to obtain a supernatant, which was used as an α-glucosidase crude enzyme solution. The amount of enzyme that decomposes 1.44 μmol of maltose for 60 minutes at 37 ° C. was defined as 1 U, and the amount of enzyme that decomposes 0.94 μmol of sucrose under the same conditions was defined as 1 U. The enzyme unit was defined using Glucose CII Test Wako (manufactured by Wako Pure Chemical Industries, Ltd.).

(Test Example 2)
The activity inhibition experiment for maltase, one of α-glucosidases, was performed according to the following method. After adding 30 μl of 250 mM maleate buffer, 20 μl of maleate buffer or Hermanus extract, and 50 μl of diluted crude enzyme solution (4U), the mixture was stirred and preheated at 37 ° C. for 5 minutes. The enzyme reaction was started by adding 100 μl of a substrate, 200 mM maltose dissolved in 250 mM maleate buffer. After reaction at 37 ° C. for 30 minutes, the reaction was stopped by heating at 100 ° C. for 10 minutes. The control group was similarly prepared using a crude enzyme solution previously inactivated by preheating at 100 ° C. for 10 minutes.

(Test Example 3)
The amount of glucose produced is maintained by high-performance liquid chromatography (JASCO Corp., Gulliver series) connected with a capsule pack NH2 UG80 (Shiseido Co., Ltd.) column and a differential refractometer (JASCO Corp .; RI930 Intelligent RI Detector). It was expressed as the area of the peak detected over time. The analysis conditions were 75% acetonitrile diluted with ultrapure water as the mobile phase, the sample injection volume was 25 μl, the column temperature was 35 ° C., and the flow rate was 1 ml / min.

  In the calculation of the inhibition rate, the activity when no Hermanus extract was included was defined as 100, and the activity obtained when the Hermanus extract was added was subtracted from 100 as the inhibition rate (%). As a result, the inhibition rate of the Hermanus extract for maltase activity was 93.7% as shown in FIG.

(Comparative Example 1)
Similarly, an activity inhibition experiment was performed on the guava extract. As a result, the inhibition rate of guava extract against maltase activity was 73.2% as shown in FIG.

(Comparative Example 2)
As an α-glucosidase inhibitor, acarbose (Acarbose: manufactured by Toronto Research Chemicals) was added to a concentration of 0.1 μg / ml, and a maltase activity inhibition experiment was conducted. As a result, the inhibition rate of acarbose on maltase activity was 56.8% as shown in FIG.

(Test Example 4)
The activity inhibition experiment for α-glucosidase, sucrase, was carried out in substantially the same manner as the maltase activity inhibition experiment. However, 1M sucrose dissolved in 250 mM maleate buffer was used as the substrate. As a result, the inhibition rate of the Hermanus extract for sucrase activity was 72.6% as shown in FIG.

(Comparative Example 3)
Similarly, an activity inhibition experiment was performed on the guava extract. As a result, the inhibition rate of guava extract against sucrase activity was 53.7% as shown in FIG.

(Comparative Example 4)
Acarbose (manufactured by Toronto Research Chemicals) was added as an α-glucosidase inhibitor to a concentration of 10 μg / ml, and a sucrase activity inhibition experiment was conducted. As a result, the inhibition rate of acarbose on sucrase activity was 61.0% as shown in FIG.

(Test Example 5)
The preparation of α-amylase and the definition of the enzyme unit are as follows. To 10 mg of α-amylase derived from porcine pancreas (manufactured by Sigma), 10 ml of 200 mM Tris-maleic acid buffer (pH 7.0) containing 5 mM calcium chloride was added and dissolved by stirring. Insoluble precipitate was removed by centrifugation at 15,000 xg for 5 minutes. The α-amylase activity was defined as 1 U, which is the amount of enzyme that degrades 4.4 mg of starch at 37 ° C for 60 minutes. The enzyme unit is defined as 0, 0.5, 1, 2% starch, colored by the iodine starch reaction described below, and the absorbance at 655 nm is measured with an absorptiometer (Bio-Rad, Smart Spec TM Plus). And determined from the obtained calibration curve.

(Test Example 6)
The α-amylase activity inhibition experiment was performed according to the following method. Add 30 μl of 200 mM Tris-maleic acid buffer solution (pH 7.0), 20 μl of Tris-maleic acid buffer solution or Hermanus extract, 50 μl of diluted crude enzyme solution (4 U), stir, and preliminarily add at 37 ° C for 5 minutes. Warm. The enzyme reaction was started by adding 100 μl of a substrate, 4% starch solution dissolved in 200 mM Tris-maleic acid buffer. After reacting at 37 ° C. for 30 minutes, the reaction was stopped by adding 250 μl of 0.5N hydrochloric acid. The control group was similarly prepared using an α-amylase enzyme solution which had been inactivated by preheating at 100 ° C. for 30 minutes.

(Test Example 7)
The amount of remaining starch was determined by measuring the absorbance at 655 nm with an absorptiometer for a solution developed by adding 950 μl of ion exchange water and 500 μl of Lugol solution (0.0016N iodine solution) to 50 μl of the reaction solution. .

  In the calculation of the inhibition rate, the activity when no Hermanus extract was included was defined as 100, and the activity obtained when the Hermanus extract was added was subtracted from 100 as the inhibition rate (%). As a result, the inhibition rate of the Hermanus extract for α-amylase was 83.7% as shown in FIG.

(Comparative Example 5)
Acarbose (Acarbose: manufactured by Toronto Research Chemicals) was added as an α-glucosidase inhibitor to 2 μg / ml, and α-amylase activity inhibition experiments were performed. As a result, the inhibition rate of acarbose on α-amylase activity was 49.3% as shown in FIG.

  From the above Examples, Test Examples and Comparative Examples, the Hermanus extract showed 93.7% for maltase inhibition and 72.6% for sucrase inhibition, both showing higher inhibition rates than the similarly prepared guava extract. In addition, α-amylase inhibition was as high as 83.7% at the same dilution rate. The trigger for postprandial hyperglycemia is the degradation of carbohydrates by α-amylase and α-glucosidase, which contributes most to digestion among the saccharide-degrading enzymes present in the body. On the other hand, the high inhibition of the Hermanus extract of the present invention suggests that this extract is a food material that has the potential to prevent diabetes.

  The extract can be applied in the form of beverages, and the extract obtained by drying can be applied to foods that can alleviate postprandial blood glucose levels by adding to carbohydrate-rich foods (such as rice). is there. Moreover, since sucrose activity inhibition is also high, it can be applied to sucrose, which is a main raw material.

It is a result of the inhibition experiment with respect to maltase, one of α-glucosidases. Acarbose is a glucolytic enzyme inhibitor. The Acarbose bar indicates that this experiment is an inhibition experiment. The inhibition rate was 93.7% for the Hermanus extract, 73.2% for the guava extract, and 56.8% for 0.1 μg / ml Acarbose. It is the result of the inhibition experiment with respect to one of α-glucosidase, sucrase. The inhibition rate was 72.6% for the Hermanus extract, 53.7% for the guava extract, and 61.0% for 10 μg / ml Acarbose. It is a result of an α-amylase inhibition experiment. Inhibition rates were 83.7% for Hermanus extract and 49.3% for 2 μg / ml Acarbose.

Claims (6)

  A food composition comprising one or two inhibitors of α-glucosidase and α-amylase obtained by extraction from a flower of Hermanus with water or an aqueous solution.   The food composition according to claim 1, wherein the flower of the genus is makey tea.   A method for producing an inhibitor of any one or two of α-glucosidase and α-amylase, which is extracted from flowers of Hermanus with water or an aqueous solution.   A method for producing one or two inhibitors of α-glucosidase and α-amylase, characterized in that extraction is performed from flowers of Hermanus with water or an aqueous solution at 60 ° C. to 100 ° C. for 5 to 15 minutes.   A method for producing a beverage, comprising one or two inhibitors of α-glucosidase and α-amylase obtained by extraction from a flower of Hermanus with water or an aqueous solution. A method for producing a food composition, which comprises adding one or two inhibitors of α-glucosidase and α-amylase obtained by extraction from a flower of Hermanus with water or an aqueous solution to a food material.

Images